What is Achieve Life Sciences's convertible debentures?

Achieve Life Sciences (ACHV) reported convertible debentures of $9.32M in Q1 2026.

How has Achieve Life Sciences's convertible debentures changed year-over-year?

Achieve Life Sciences's convertible debentures increased by 7.7% year-over-year, from $8.66M to $9.32M.

What is the long-term trend for Achieve Life Sciences's convertible debentures?

Over 2 years (2021 to 2025), Achieve Life Sciences's convertible debentures has grown at a -13.4% compound annual growth rate (CAGR), from $14.92M to $11.19M.

Achieve Life Sciences ACHV Convertible debentures

Convertible debentures at other companies

DexComDXCM

$0—

Jade Biosciences, Inc. Common StockJBIO

$0-100%

DropboxDBX

$690.3M+0.2%

Five9FIVN

$736.37M+0.5%

Nutanix, Inc.NTNX

$1.35B+0.4%

NTS

Netskope, Inc. Class A Common StockNTSK

$713.32M—

Other financials

Income statement

See full

Net income-$10.2M+20.7%

EPS (diluted)-$0.19+48.6%

Balance sheet

See full

Cash & equivalents$28.1M+116%

Total debt$5.6M+332%

Total equity$10.7M+3.9%

Total assets$33.1M+21.0%

Cash flow

See full

Operating cash flow-$6.9M+37.5%

CapEx$750.0—

Free cash flow-$12.4M—

Valuation

See full

Market cap$585.16M+404%

Enterprise value$562.71M+439%

Returns & leverage

See full

Return on equity-496.1%-906pp

Debt / equity0.5×+0.4×

Current ratio2.6×-0.9×

Where this comes from

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleDebtNoncurrent.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's convertible debentures.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Achieve Life Sciences's convertible debentures?: Achieve Life Sciences (ACHV) reported convertible debentures of $9.32M in Q1 2026.
How has Achieve Life Sciences's convertible debentures changed year-over-year?: Achieve Life Sciences's convertible debentures increased by 7.7% year-over-year, from $8.66M to $9.32M.
What is the long-term trend for Achieve Life Sciences's convertible debentures?: Over 2 years (2021 to 2025), Achieve Life Sciences's convertible debentures has grown at a -13.4% compound annual growth rate (CAGR), from $14.92M to $11.19M.